Cyxone initiates early operations with a global contract research organization to conduct Phase 2b trial in rheumatoid arthritis
Cyxone (publ) announces today that the company has initiated an early operations agreement (EOA) with an internationally renowned contract research organization (CRO) to prepare for the upcoming clinical Phase 2b trial of Rabeximod in patients with rheumatoid arthritis. As part of the EOA, the CRO will support Cyxone in start-up and feasibility activities including finalization of the trial protocol and selection of the countries and trial sites that meet the criteria of the trial design.Cyxone is developing Rabeximod, an oral potential first line treatment for patients suffering from the